Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of moderate to severe plaque psoriasis. Topics covered include expert opinions on: UCB and Dermira announcing positive...

Gain new KOL insights on the latest events happening in the colorectal cancer (CRC) market: the release of data from the Phase III LUME-Colon 1 trial of Boehringer Ingelheim’s nintedanib in pre-treated patients...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Galapagos obtaining US and EU regulatory...

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include expert opinions on the two Phase II adjunctive studies being conducted by Roche that are evaluating...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of age-related macular degeneration (AMD). Topics covered include expert opinions on: Novartis and Ophthotech announcing...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple myeloma (MM). Topics covered include expert opinions on: Takeda receiving a recommendation for approval for...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the positive Phase II data reported...

Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA). During September 2016, the US FDA approved Amgen's Amjevita (adalimumab-atto), as a biosimilar to AbbVie's Humira for multiple...

Gain new KOL insights on the latest events happening in the head and neck squamous cell carcinoma (HNSCC) market: the accelerated FDA approval of Keytruda (pembrolizumab; Merck & Co.) for the treatment of recurrent...

Gain new KOL insights on the latest events happening in dyslipidaemia: Pfizer’s discontinuation of the development of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, bococizumab, and its Phase...

Gain new KOL insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Topics covered include expert opinions about the recent FDA label expansion of...